Novartis' once-daily oral drug Gilenya (fingolimod) received its first marketing approval after Russian regulators cleared the product for the treatment of relapsing remitting multiple sclerosis. The Swiss drugmaker expects to launch Gilenya in Russia in early 2011. In the US, where the drug is known as Gilenia, an advisory panel recommended approval of the product in June, with a final decision from the FDA anticipated later this month.
Reference Articles
Novartis announces Russian regulatory approval for Gilenya, a once-daily oral multiple sclerosis therapy and first in a new class - (Novartis)
Novartis' Gilenya receives Russian regulatory approval - (Stock Markets Review)
Russia becomes first to approve Novartis drug Gilenya (free preview) - (The Wall Street Journal)
**Published in "FW Pharma"
Diario digital con noticias de actualidad relacionadas con el mundo de la salud. Novedades, encuestas, estudios, informes, entrevistas. Con un sencillo lenguaje dirigido a todo el mundo. Y algunos consejos turísticos para pasarlo bien
Traductor
Subscribe to:
Post Comments (Atom)
CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies
Copyright © Noticia de Salud
Chronic pain should be controlled in a fast and effective, so doctors prescribe painkillers such as Vicodin, hydrocodone, norco which are medicines that have side effects but are used to control chronic pain.
ReplyDelete